Mei Mei Hu
Founder at VAXXINITY, INC.
Net worth: 9 M $ as of 29/04/2024
Mei Mei Hu active positions
| Companies | Position | Start | End |
|---|---|---|---|
| VAXXINITY, INC. | Director/Board Member | 31/12/2013 | - |
| Chief Executive Officer | 31/12/2013 | - | |
| Founder | 31/12/2013 | - | |
| President | 31/12/2013 | - | |
| UNITED BIOPHARMA INC | Director/Board Member | 29/02/2020 | - |
Covaxx, Inc.
 Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Chief Executive Officer | 29/02/2020 | - |
Career history of Mei Mei Hu
Former positions of Mei Mei Hu
| Companies | Position | Start | End |
|---|---|---|---|
| Shen Lian Biotechnology Co. Ltd. | Director/Board Member | 31/12/2009 | 31/12/2013 |
| United Neuroscience LLC | Director/Board Member | 30/09/2014 | - |
Training of Mei Mei Hu
| University of Pennsylvania | Undergraduate Degree |
| Harvard Law School | Graduate Degree |
Statistics
International
| United States | 6 |
| Taiwan | 2 |
| China | 2 |
Operational
| Director/Board Member | 4 |
| Chief Executive Officer | 2 |
| Founder | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| VAXXINITY, INC. | Health Technology |
| Private companies | 4 |
|---|---|
United BioPharma, Inc.
 United BioPharma, Inc. Pharmaceuticals: MajorHealth Technology United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan. | Health Technology |
Covaxx, Inc.
Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Health Technology |
| United Neuroscience LLC | |
| Shen Lian Biotechnology Co. Ltd. |
- Stock Market
- Insiders
- Mei Mei Hu
- Experience
